Compare TG & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TG | BDSX |
|---|---|---|
| Founded | 1988 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Precision Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.6M | 276.2M |
| IPO Year | 1994 | 2020 |
| Metric | TG | BDSX |
|---|---|---|
| Price | $7.21 | $21.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $39.00 |
| AVG Volume (30 Days) | ★ 181.3K | 90.6K |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 151.06 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $800,821,000.00 | $88,499,000.00 |
| Revenue This Year | N/A | $26.51 |
| Revenue Next Year | N/A | $20.25 |
| P/E Ratio | $23.62 | ★ N/A |
| Revenue Growth | 8.29 | ★ 24.08 |
| 52 Week Low | $6.25 | $5.26 |
| 52 Week High | $10.53 | $31.97 |
| Indicator | TG | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 31.27 |
| Support Level | $7.16 | $19.26 |
| Resistance Level | $8.21 | $24.82 |
| Average True Range (ATR) | 0.30 | 1.58 |
| MACD | 0.04 | -0.46 |
| Stochastic Oscillator | 17.32 | 1.25 |
Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.